These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29466466)

  • 1. Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural equation modeling approach.
    Romero-Ibarguengoitia ME; Vadillo-Ortega F; Caballero AE; Ibarra-González I; Herrera-Rosas A; Serratos-Canales MF; León-Hernández M; González-Chávez A; Mummidi S; Duggirala R; López-Alvarenga JC
    PLoS One; 2018; 13(2):e0193138. PubMed ID: 29466466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A targeted metabolomic profiling of plasma acylcarnitines in nonalcoholic fatty liver disease.
    Chang Y; Gao XQ; Shen N; He J; Fan X; Chen K; Lin XH; Li HM; Tian FS; Li H
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7433-7441. PubMed ID: 32706083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses.
    Li Z; Lin M; Liu C; Wang D; Shi X; Chen Z; Liu Y; Yang S; Li X
    Cytokine; 2018 Aug; 108():145-150. PubMed ID: 29609136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
    Gastaldelli A
    Clin Sci (Lond); 2017 Nov; 131(22):2701-2704. PubMed ID: 29109303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A family history of type 2 diabetes as a predictor of fatty liver disease in diabetes-free individuals with excessive body weight.
    De Pergola G; Castellana F; Zupo R; De Nucci S; Panza F; Castellana M; Lampignano L; Di Chito M; Triggiani V; Sardone R; Giannelli G
    Sci Rep; 2021 Dec; 11(1):24084. PubMed ID: 34916558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach.
    Feldman A; Eder SK; Felder TK; Paulweber B; Zandanell S; Stechemesser L; Schranz M; Strebinger G; Huber-Schönauer U; Niederseer D; Patsch W; Weghuber D; Tevini J; Datz C; Aigner E
    Diabetes Metab; 2019 Apr; 45(2):132-139. PubMed ID: 30266576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma.
    Enooku K; Nakagawa H; Fujiwara N; Kondo M; Minami T; Hoshida Y; Shibahara J; Tateishi R; Koike K
    Sci Rep; 2019 Jul; 9(1):10663. PubMed ID: 31337855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease.
    Goffredo M; Santoro N; Tricò D; Giannini C; D'Adamo E; Zhao H; Peng G; Yu X; Lam TT; Pierpont B; Caprio S; Herzog RI
    Nutrients; 2017 Jun; 9(7):. PubMed ID: 28640216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance.
    Gaggini M; Carli F; Rosso C; Buzzigoli E; Marietti M; Della Latta V; Ciociaro D; Abate ML; Gambino R; Cassader M; Bugianesi E; Gastaldelli A
    Hepatology; 2018 Jan; 67(1):145-158. PubMed ID: 28802074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
    Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
    Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Risk Factors Associated With Blood Metabolite Concentrations and Their Alterations During a 4-Year Period in a Population-Based Cohort.
    Lacruz ME; Kluttig A; Tiller D; Medenwald D; Giegling I; Rujescu D; Prehn C; Adamski J; Frantz S; Greiser KH; Emeny RT; Kastenmüller G; Haerting J
    Circ Cardiovasc Genet; 2016 Dec; 9(6):487-494. PubMed ID: 27784734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes Mellitus, Nonalcoholic Fatty Liver Disease, and Conjugated Linoleic Acid (Omega 6): What Is the Link?
    Hegazy M; Elsayed NM; Ali HM; Hassan HG; Rashed L
    J Diabetes Res; 2019; 2019():5267025. PubMed ID: 31089474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Acylcarnitines and Amino Acid Levels As an Early Complex Biomarker of Propensity to High-Fat Diet-Induced Obesity in Mice.
    Horakova O; Hansikova J; Bardova K; Gardlo A; Rombaldova M; Kuda O; Rossmeisl M; Kopecky J
    PLoS One; 2016; 11(5):e0155776. PubMed ID: 27183228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of plasma acylcarnitines before and after weight loss in obese subjects.
    Schooneman MG; Napolitano A; Houten SM; Ambler GK; Murgatroyd PR; Miller SR; Hollak CE; Tan CY; Virtue S; Vidal-Puig A; Nunez DJ; Soeters MR
    Arch Biochem Biophys; 2016 Sep; 606():73-80. PubMed ID: 27444119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
    Alkassabany YM; Farghaly AG; El-Ghitany EM
    Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes.
    Wewer Albrechtsen NJ; Junker AE; Christensen M; Hædersdal S; Wibrand F; Lund AM; Galsgaard KD; Holst JJ; Knop FK; Vilsbøll T
    Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G91-G96. PubMed ID: 28971838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
    Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
    J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD).
    Ajaz S; McPhail MJ; Gnudi L; Trovato FM; Mujib S; Napoli S; Carey I; Agarwal K
    Mitochondrion; 2021 Mar; 57():119-130. PubMed ID: 33387664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.